PBA
TCRX icon

Paradigm Biocapital Advisors’s TScan Therapeutics TCRX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-353,886
Closed -$2.07M – 40
2024
Q2 		$2.07M Buy
+353,886
New +$2.79M 0.08% 35

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Paradigm Biocapital Advisors's TCRX Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of TScan Therapeutics (TCRX) in Q3 2024, closing a stake of 353,886 shares — an estimated $2.07M sold.

Paradigm Biocapital Advisors first reported a position in TCRX in Q2 2024 and held it in 1 quarter. The position peaked at $2.07M in Q2 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining TScan Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 353,886 TScan Therapeutics shares in Q3 2024, an estimated $2.07M.
  • Paradigm Biocapital Advisors first reported a position in TScan Therapeutics in Q2 2024 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's TScan Therapeutics position peaked at $2.07M in Q2 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.